نتایج جستجو برای: prasugrel
تعداد نتایج: 1097 فیلتر نتایج به سال:
Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissoci...
Background. Acute Coronary Syndrome (ACS) is a clinical condition encompassing ST Segment Elevation Myocardial Infarction (STEMI), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and Unstable Angina (UA) and is characterized by ruptured coronary plaque, ischemic stress, and/or myocardial injury. Emergency department (ED) physicians are on the front lines of ACS management. The role of ...
Commentary Clopidogrel, a prodrug with variable metabolism to the active form, has delayed onset of action often resulting in need for a glycoprotein IIb/IIIa–receptor inhibitor to ensure adequate platelet inhibition in patients having PCI, but at the expense of increased bleeding. Prasugrel and ticagrelor are new oral antiplatelet agents that overcome some clopidogrel disadvantages: Prasugrel ...
Use of antiplatelet agents is becoming increasingly common, and their management may require new strategies if neuroaxial techniques are to be employed in patients who will not tolerate discontinuation of antiplatelet therapy. The patient was a 46-year-old man with a past medical history significant for coronary artery disease and who had undergone 14 stents. He developed stent thrombosis (ST) ...
Fatal Bleedings With Prasugrel as Part of Triple Antithrombotic Therapy Hemorragias mortales relacionadas con un tratamiento antitrombótico triple que incluye prasugrel To the Editor, Triple antithrombotic therapy with aspirin, clopidogrel, and warfarin is used in about 5% of patients after coronary stent implantation, mostly due to atrial fibrillation and left ventricular thrombosis. 1 This an...
BACKGROUND No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y12 inhibitors were first demonstrated relative to clopidogrel. METHODS This academic study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with pr...
Abstract High on-treatment platelet reactivity (HPR) with P2Y12 receptor antagonists in patients treated dual antiplatelet therapy (DAPT) is strongly associated adverse ischemic events after percutaneous coronary intervention (PCI). This prospective study was conducted to assess individual response and HPR medications post-PCI cases by thromboelastography mapping (TEG-PM). Total 82 who were on ...
Thienopyridine derivatives such as clopidogrel have been shown to reduce the incidence of death in patients undergoing percutaneous coronary intervention when used in conjunction with aspirin. Recently, a new thienopyridine, prasugrel, significantly reduced the primary endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke to 9.9% compared to 12.1% for clopidogrel...
3 DMD #20248 Prasugrel is a novel thienopyridine prodrug with demonstrated inhibition of platelet aggregation and activation. The biotransformation of prasugrel to its active metabolite, R-138727, requires ester bond hydrolysis, forming the thiolactone R-95913, followed by cytochrome P450-mediated metabolism to the active metabolite. The presumed role of the human liverand intestinaldominant ca...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید